SLNO vs. INMD, BLFS, CNMD, RYTM, LRMR, EDAP, FONR, RMTI, LIVN, and ITGR
Should you be buying Soleno Therapeutics stock or one of its competitors? The main competitors of Soleno Therapeutics include InMode (INMD), BioLife Solutions (BLFS), CONMED (CNMD), Rhythm Pharmaceuticals (RYTM), Larimar Therapeutics (LRMR), Edap Tms (EDAP), FONAR (FONR), Rockwell Medical (RMTI), LivaNova (LIVN), and Integer (ITGR). These companies are all part of the "medical" sector.
Soleno Therapeutics (NASDAQ:SLNO) and InMode (NASDAQ:INMD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, community ranking, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.
Soleno Therapeutics received 143 more outperform votes than InMode when rated by MarketBeat users. However, 75.12% of users gave InMode an outperform vote while only 71.43% of users gave Soleno Therapeutics an outperform vote.
InMode has a net margin of 38.84% compared to Soleno Therapeutics' net margin of 0.00%. InMode's return on equity of 26.15% beat Soleno Therapeutics' return on equity.
Soleno Therapeutics presently has a consensus price target of $60.33, suggesting a potential upside of 48.42%. InMode has a consensus price target of $32.80, suggesting a potential upside of 68.21%. Given InMode's higher probable upside, analysts clearly believe InMode is more favorable than Soleno Therapeutics.
97.4% of Soleno Therapeutics shares are owned by institutional investors. Comparatively, 68.0% of InMode shares are owned by institutional investors. 12.3% of Soleno Therapeutics shares are owned by company insiders. Comparatively, 6.9% of InMode shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Soleno Therapeutics and Soleno Therapeutics both had 5 articles in the media. InMode's average media sentiment score of 1.12 beat Soleno Therapeutics' score of 0.75 indicating that InMode is being referred to more favorably in the news media.
Soleno Therapeutics has a beta of -1.51, suggesting that its stock price is 251% less volatile than the S&P 500. Comparatively, InMode has a beta of 2.2, suggesting that its stock price is 120% more volatile than the S&P 500.
InMode has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.
Summary
InMode beats Soleno Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Soleno Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLNO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SLNO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Soleno Therapeutics Competitors List
Related Companies and Tools
